Point-of-care CAR-T shows ‘promising’ efficacy, safety for B-cell non-Hodgkin lymphoma

Developing a new CD19-directed CAR-T for patients with B-cell non-Hodgkin lymphoma is necessary despite an already crowded market of commercially available therapies because approximately 60% of patients who receive the therapy lack a durable response and will experience disease relapse, according to Manali Kamdar, associate professor of medicine/hematology at University of Colorado School of Medicine and clinical director of lymphoma services at CU Cancer Center.